Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34843940

Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Ann Oncol
Publication date
2022 Feb
First author
Tanizaki J

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Ann Oncol. 2022 Sep;33(9):984-985. doi: 10.1016/j.annonc.2022.05.008.
    note
    Source null
    related pmid
    35636622
    relationship
    Comment in
  2. citation
    Ann Oncol. 2022 Oct;33(10):1083-1084. doi: 10.1016/j.annonc.2022.06.006.
    note
    Source null
    related pmid
    35772666
    relationship
    Comment in

Authors and identifiers

  1. name
    Tanizaki J
    type
    Author
  2. name
    Yonemori K
    type
    Author
  3. name
    Akiyoshi K
    type
    Author
  4. name
    Minami H
    type
    Author
  5. name
    Ueda H
    type
    Author
  6. name
    Takiguchi Y
    type
    Author
  7. name
    Miura Y
    type
    Author
  8. name
    Segawa Y
    type
    Author
  9. name
    Takahashi S
    type
    Author
  10. name
    Iwamoto Y
    type
    Author
  11. name
    Kidera Y
    type
    Author
  12. name
    Fukuoka K
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Tanizaki J
    type
    Author
  2. name
    Yonemori K
    type
    Author
  3. name
    Akiyoshi K
    type
    Author
  4. name
    Minami H
    type
    Author
  5. name
    Ueda H
    type
    Author
  6. name
    Takiguchi Y
    type
    Author
  7. name
    Miura Y
    type
    Author
  8. name
    Segawa Y
    type
    Author
  9. name
    Takahashi S
    type
    Author
  10. name
    Iwamoto Y
    type
    Author
  11. name
    Kidera Y
    type
    Author
  12. name
    Fukuoka K
    type
    Author
bibliography ids
  1. nci-bib-8c11cc3cd6dc85eca2a2272a
book metadata
content sha256
f9f31e388fb876cdd782396737126b66f0f82a116a814f68766817647a1bfd41
document type
citation
dois
  1. 10.1016/j.annonc.2021.11.009
electronic publication date
display
2021 Nov 26
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34843940
immutable id
pubmed:34843940@f9f31e388fb876cdd782396737126b66f0f82a116a814f68766817647a1bfd41
journal
abbreviation
Ann Oncol
issn electronic
1569-8041
issn print
0923-7534
issue
2
name
Annals of oncology : official journal of the European Society for Medical Oncology
nlm unique id
9007735
pages
216-226
volume
33
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Ann Oncol. 2022 Sep;33(9):984-985. doi: 10.1016/j.annonc.2022.05.008.
    note
    Source null
    related pmid
    35636622
    relationship
    Comment in
  2. citation
    Ann Oncol. 2022 Oct;33(10):1083-1084. doi: 10.1016/j.annonc.2022.06.006.
    note
    Source null
    related pmid
    35772666
    relationship
    Comment in
outcomes validated
false
pmid
34843940
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
867e3282907d16aafd1a9f4ceea0c25de03df50a0dd37ae64b5e6911b9b98100
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Feb
precision
month
year
2022
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34843940/
title
Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary.

Preserved source evidence · Not medical advice